AbbVie Q3 Revenue Rises 10.3% to $17.4 Billion; Adjusted EPS Reaches $3.82

What happened

AbbVie reported third-quarter 2026 revenue of $17.404 billion, up 10.3% from a year earlier. GAAP diluted earnings per share were $2.37 and adjusted diluted earnings per share were $3.82. The company raised its 2026 adjusted earnings guidance and announced a 5.2% dividend increase.

Confirmed

Global impact / market context

Rising revenue and higher adjusted earnings per share, which is profit divided across shares, suggest AbbVie is selling more and keeping more profit per sale. The raised guidance and bigger dividend signal management expects continued cash generation, which can support shareholder payouts and fund acquisitions.

Analyst inference

AbbVie depends on newer immunology drugs Skyrizi and Rinvoq as Humira sales decline. Growth in neuroscience products adds another revenue source. The completed Apogee acquisition brings early-stage immunology assets, meaning future spending on research and deal costs could weigh on reported profit.

Analyst inference

What to watch

1. AbbVie raised 2026 adjusted diluted earnings per share guidance to a range of $13.95 to $13.99, so investors can compare later quarterly results against this company target. Confirmed
2. Watch whether Skyrizi and Rinvoq continue replacing declining Humira revenue, since slower growth in these drugs would pressure total sales and the cash available for dividends. Analyst inference
3. Track spending on research and milestone payments tied to the Apogee deal, because these costs reduce adjusted earnings, as shown by the $0.11 per-share hit this quarter. Proposed

Evidence

• Original source link unavailable